NET Kanker

Phase 3 Trail of 117 Lu-Dotatate for Midgut Neuroendocrine Tumors
Auteurs: Baum RP, Benson A, Berlin J, Bushnell D, Caplin M, Chasen B, Delpassand E, El-Haddad G, Erion JL, Grande E, Hendifar A, Hobday T, Jacene H, Krenning EP, Kulkarni HR, Kulke MH, Kunz PL, Kwekkeboom DJ, Lebtahi R, Lopera Sierra M, Mittra E, Mora J, O'Dorisio TM, Pavel ME, Reed N, Ruszniewski P, Santoro P, Seregni E, Srirajaskanthan R, Strosberg J, Thevenet T, Van Cutsem E, Wolin E, Yao J, Öberg K
Categorieën: NET Kanker
Samenvatting

BACKGROUND:

Patients with advanced midgut neuroendocrine tumors who have had disease progression during first-line somatostatin analogue therapy have limited therapeutic options. This randomized, controlled trail evaluated the efficacy and safety of lutetium-177 (177Lu)-Dotatate in patients with advanced, progressive, somatostatin-receptor-positive midgut neuroendocrine

Lees meer
Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival.
Auteurs: Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, Feelders RA, van Aken MO, Krenning EP
Categorieën: NET Kanker
Samenvatting

PURPOSE:

Despite the fact that most gastroenteropancreatic neuroendocrine tumors (GEPNETs) are slow-growing, median overall survival (OS) in patients with liver metastases is 2 to 4 years. In metastatic disease, cytoreductive therapeutic options are limited. A relatively new therapy is peptide receptor radionuclide therapy with the radiolabeled somatostatin analog [(177)Lu-DOTA(0),Tyr(3)]octreotate. Here we report on the toxicity and efficacy of this treatment, performed in over 500 patients.

PATIENTS AND METHODS:

Lees meer
Lutetium-labelled peptides for therapy of neuroendocrine tumours.
Auteurs: Kam BL, Teunissen JJM, Krenning EP, de Herder WW, Khan S, van Vliet EI, Kwekkeboom DJ
Categorieën: NET Kanker, PRRT
Samenvatting Krenning EP Treatment with radiolabelled somatostatin analogues is a promising new tool in the management of patients with inoperable or metastasized neuroendocrine tumours. Symptomatic improvement may occur with (177)Lu-labelled somatostatin analogues that have been used for peptide receptor radionuclide therapy (PRRT). The results obtained with (177)Lu-[DOTA(0),Tyr(3)]octreotate (DOTATATE) are very encouraging in terms of tumour regression. Dosimetry studies with (177)Lu-DOTATATE as well as the limited side effects with additional cycles
Lees meer